cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
BioRegenEx · Research

Understanding Exosome Particle Counts and Concentrations

← Back to Research Library

Research-grade exosome products are often described by a particle count — for example, billions of particles per dose. Understanding what these numbers mean, and what they do not, helps when comparing preparations. This overview is provided for educational and research purposes only.

What \”particles per dose\” describes

A particle count reflects the concentration of vesicles in a preparation, typically measured by methods such as nanoparticle tracking analysis. It is one objective, quantifiable property of MSC-derived exosomes and is commonly reported on a Certificate of Analysis.

Why count alone is not the whole story

Particle concentration is meaningful only alongside the other measurements that define a preparation — size distribution, identity, purity, and sterility. A high particle count from an uncharacterized source tells you less than a documented count backed by full characterization. Numbers should be interpreted in context, not in isolation.

How to compare preparations fairly

  • Compare counts measured by the same or comparable methods
  • Confirm the count appears on a per-lot, third-party COA
  • Read the count alongside size, purity, and sterility data
  • Treat unverified \”potency\” claims with appropriate skepticism

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease and are supplied for research use only. Particle counts describe a measured property and do not imply any clinical effect. This content is for educational and informational purposes and does not constitute medical advice.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.